• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Blog
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    Medical
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training
Pharmintel

Fabry’s disease Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Fabry’s disease.
  • The report assesses Fabry’s disease pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Fabry’s disease pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Fabry’s disease ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

Research Corporation Technologies, Shire, Genzyme Corporation, Avigen, Large Scale Biology Corporation (CEASED), Amicus Therapeutics, Protalix Biotherapeutics, iBio Inc, Green Cross, ISU Abxis, Actelion Pharmaceuticals, Bio Sidus S.A., JCR Pharmaceuticals, AVROBIO, Greenovation Biotech, Sangamo Therapeutics

Key Drugs:

Alpha-antitrypsin – Arriva/Hyland Immuno, Recombinant human alpha-1 antitrypsin, VX 563, CTX 100, Small interfering RNA-based therapeutics, AGTC 0106, Alpha-1 antitrypsin deficiency therapy, Alpha-1 antitrypsin deficiency gene therapy, Alpha-1 antitrypsin, RNAi therapeutics, Human amniocyte-derived protein therapeutics, AAT-Fc – InhibRx, Biotherapeutic proteins

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8
Price:

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry





Leave a Reply

Your email address will not be published.

Contact
+91 9643310025, 9643312749
© 2019 Pharmintel